Literature DB >> 32156802

Inappropriate use of progression-free survival in cancer drug approvals.

Huseyin Naci1, Courtney Davis2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32156802     DOI： 10.1136/bmj.m770

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries.

Authors:  Carlos E Durán; Martín Cañás; Martín A Urtasun; Monique Elseviers; Tatiana Andia; Robert Vander Stichele; Thierry Christiaens
Journal:  Rev Panam Salud Publica       Date:  2021-04-09

Review 2.  Bias against Vitamin C in Mainstream Medicine: Examples from Trials of Vitamin C for Infections.

Authors:  Harri Hemilä; Elizabeth Chalker
Journal:  Life (Basel)       Date:  2022-01-03

3.  Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis.

Authors:  Alberto Farina; Federico Moro; Frederick Fasslrinner; Annahita Sedghi; Miluska Bromley; Timo Siepmann
Journal:  Pharmacol Res Perspect       Date:  2021-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.